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LEARNING OBJECTIVES
After completing this course, the reader will be able to:
1. Evaluate early data regarding the impact of daily vaginal testosterone on estradiol and testosterone levels in breast
cancer patients receiving treatment with aromatase inhibitors.
2. Explain the potential clinical benefits of vaginal testosterone therapy to treat vaginal atrophy in women with
breast cancer receiving long-term aromatase inhibitor therapy.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Purpose. Controversy exists about whether vaginal es-
trogens interfere with the efficacy of aromatase inhibi-
tors (AIs) in breast cancer patients. With the greater
incidence of vaginal atrophy in patients on AIs, a safe
and effective nonestrogen therapy is necessary. We hy-
pothesized that vaginal testosterone cream could safely
treat vaginal atrophy in women on AIs.
Methods. Twenty-one postmenopausal breast cancer
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patients on AIs with symptoms of vaginal atrophy were
treated with testosterone cream applied to the vaginal
epithelium daily for 28 days. Ten women received a dose
of 300 g, 10 received 150 g, and one was not evalu-
able. Estradiol levels, testosterone levels, symptoms of
vaginal atrophy, and gynecologic examinations with pH
and vaginal cytology were compared before and after
therapy.
Results. Estradiol levels remained suppressed after
treatment to <8 pg/mL. Mean total symptom scores im-
proved from 2.0 to 0.7 after treatment (p < .001) and
remained improved 1 month thereafter (p  .003). Dys-
pareunia (p  .0014) and vaginal dryness (p <.001) im-
proved. The median vaginal pH decreased from 5.5 to
5.0 (p  .028). The median maturation index rose from
20% to 40% (p < .001). Although improvement in total
symptom score was similar for both doses (1.3 for 300
g, 0.8 for 150 g; p  .37), only the 300-g dose was
associated with improved pH and maturation values.
Conclusions. A 4-week course of vaginal testosterone
was associated with improved signs and symptoms of
vaginal atrophy related to AI therapy without increas-
ing estradiol or testosterone levels. Longer-term trials
are warranted. The Oncologist 2011;16:424–431
INTRODUCTION
Aromatase inhibitors (AIs) increase the frequency and
complicate the treatment of vaginal atrophy in breast
cancer patients [1, 2]. Suppression of estradiol levels by
AIs alters the vaginal epithelium, rendering it drier, thin-
ner, and less elastic. In the Arimidex, Tamoxifen, Alone
or in Combination trial, vaginal dryness was observed in
16.3% and dyspareunia was observed in 17.8% of anas-
trozole-treated patients, but in only 8.4% and 7.5% of ta-
moxifen-treated patients, respectively [2]. As AIs are
used more frequently in the growing population of post-
menopausal women with hormone receptor–positive
breast cancer, this serious complication of therapy that
dramatically affects quality of life will become more
common [3].
Treatment of vaginal atrophy in women on AIs is con-
troversial. The most effective treatment for this condi-
tion is local estrogens [4]. Although neither topical
estrogen creams nor vaginal estrogen tablets raise estro-
gen to premenopausal levels, several reports suggest that
they may compromise the suppression of estrogen by
AIs, theoretically putting the patient at higher risk for
breast cancer recurrence [5]. In 2006, Kendall and col-
leagues found elevated estradiol levels in six of seven
women on AIs treated with -estradiol tablets or cream
[6]. Mean serum estradiol levels were 5 pmol/L (1.36
pg/mL) before treatment, rose to a maximum of 72
pmol/L (19.6 pg/mL) at 2 weeks, and remained elevated
for several months in some patients. A subsequent trial
found a greater rise in estradiol in patients using an es-
tradiol tablet than in those using a vaginal estradiol ring
[7]. These small studies presented only short-term fol-
low-up results and no data on breast cancer outcomes, yet
many patients and physicians are avoiding all estrogen
therapy in this setting.
Alternatives to topical estrogens include vaginal
moisturizers such as Replens (Lil’ Drug Store Products,
Inc., Cedar Rapids, IA) and lubricants such as K-Y jelly
(Johnson & Johnson Inc., New Brunswick, NJ). These
are often useful, but are generally not as effective as es-
trogen [4]. Replens improves vaginal moisture and
elasticity and restores pH; however, as a bioadhesive gel
it does not reverse the cytologic effects of atrophy. Cy-
tologic studies show improvement in cell size but no im-
provement in maturation values [3, 8 –10]. Anecdotal
reports in the online breast cancer community have sug-
gested that testosterone might have clinical efficacy.
Testosterone induces proliferation of the vaginal epithe-
lium, and because its conversion to estrogen is blocked
by AIs, we hypothesized that topical testosterone would
reverse the atrophic changes of estrogen suppression
without interfering with the activity of the AI [11–14].
In this study, we sought to determine the impact of
vaginal testosterone on estradiol levels and, secondarily,
on pathological and clinical measures of vaginal atrophy
in women with breast cancer on long-term AI therapy.
METHODS
Design
In this phase I/II pilot study, we assessed whether a 28-day
trial of daily vaginal testosterone affected estradiol and tes-
tosterone levels in breast cancer patients on AIs. We then
evaluated whether testosterone could improve the symp-
toms and signs of vaginal atrophy. Finally, a dose reduction
was planned if symptom improvement was noted at the ini-
tial dose.
Testosterone cream was prepared by a specialty com-
pounder using testosterone United States Pharmacopeia mi-
cronized powder made into a paste with polysorbate 80
National Formulary (NF) liquid in an emollient cream base.
The first 10 patients received a dose of 300 g of testoster-
one whereas the second 10 patients were given a dose of
150 g. The 300-g dose was compounded with 13.5 mg
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and the 150-g dose was compounded with 6.75 mg of tes-
tosterone propionate in 0.45 mL of polysorbate NF liquid
and sufficient emollient cream base to make 45 g total. A
calibrated vaginal applicator was supplied to measure out
daily doses of 1 g each. The cream was applied daily for 28
consecutive days. A 300-g daily dose approximates the
transdermal testosterone dose given to women with hypo-
active sexual desire and is much lower than the dose given
to men with low androgen states [15–17]. Because approx-
imately 10% of transdermal testosterone is absorbed sys-
temically, this dose was considered unlikely to raise serum
androgen levels above normal female values [18, 19]. Even
if androgen levels were elevated, serum estrogen levels
were not expected to increase in the context of aromatase
inhibition.
Before starting the intervention, patients received in-
struction on how to apply the cream using a diagram of the
perineum. They were instructed to apply a portion of the
cream to the inner labia minora and external vaginal mu-
cosa digitally and the remainder of the cream to the inner
vaginal mucosa digitally or with the applicator. They were
instructed not to apply the cream to the clitoris, the labia
majora, or any nonintact skin to avoid irritation. Patients
were prohibited from using local therapies, including topi-
cal estrogen or vaginal lubricants.
Setting and Patients
Twenty-one breast cancer patients were enrolled from the
medical oncology clinics of Fletcher Allen Health Care and
Memorial Hospital of Rhode Island between December
2006 and October 2009. Patients were recruited if they had
reported vaginal symptoms to their providers. Charts were
also reviewed to identify breast cancer patients on AIs and
providers were asked to question patients about symptoms
of vaginal atrophy. Patients were eligible if they were un-
dergoing primary or adjuvant treatment with an AI for a his-
tologically or cytologically confirmed breast cancer and
reported vaginal itching, dryness, or dyspareunia. Only
postmenopausal patients with a life expectancy 2 months
and an Eastern Cooperative Oncology Group (ECOG) per-
formance status score 3 were eligible [20]. Postmeno-
pausal status was defined as the absence of menses for 12
months or a follicle-stimulating hormone level 25 mIU/
mL. Patients undergoing active chemotherapy or radiother-
apy or on medications intended to suppress ovarian
function were not eligible. Patients using vaginal estrogen
within the preceding 2 months were not eligible. The study
was approved by the institutional review board of each in-
stitution before patients were enrolled. Written informed
consent meeting all federal, state, and institutional guide-
lines was obtained from all patients.
Measurements
High-sensitivity assays for estradiol were done at baseline
and after 4 weeks of treatment. If post-treatment levels were
elevated, they were repeated 4 weeks after treatment was
completed. The assay used extraction and radioimmunoas-
say plus chromatography to detect changes in plasma estra-
diol of 1–5 pg/mL [21–24]. The analyst was blind to the
identity of the patient and to whether samples were obtained
before or after treatment.
Patients completed symptom questionnaires at baseline,
at the end of the 4-week treatment and 4 weeks later at an
8-week follow-up visit. The questionnaire was adapted
from previous studies of estrogen therapy for vaginal atro-
phy [25–27]. The patient was asked to rate the severity of
“dryness of the vagina,” “itching or irritation of the vagina
or vulva,” and “pain with intercourse” on a four-point scale
(0, none; 1, mild; 2, moderate; 3, severe). Scores for all
three symptoms were summed for a total symptom score.
Possible scores were in the range of 0–12, or 0–8 for pa-
tients who rated dyspareunia as “not applicable” because of
a lack of sexual activity.
Before and after the study intervention, a gynecologic
examination was performed by one of three providers who,
though not blinded to intervention status, performed inde-
pendent assessments before starting therapy and within 72
hours of its completion. These included examination of the
external genitalia, a speculum vaginal examination, and a
pH measurement. Samples of vaginal epithelial cells were
obtained with vaginal brushing. Microscopic evaluation of
the vaginal epithelium was performed by one pathologist
who was blinded to the identity of the patient and to whether
samples were obtained before or after treatment. The mat-
uration index was calculated from vaginal cytology using
the Kupperman index [28].
Side effects were monitored throughout the study, in-
cluding local reactions such as rash or pruritis, as well as
hirsutism, acne, thrombosis, headache, depression, and sys-
temic rash.
Hematocrit, liver function tests, lipid panels, and testos-
terone levels were obtained on all patients before and after
therapy. Elevated levels were retested 1 month after therapy
was completed.
Statistical Methods
The primary endpoint was maintenance of estradiol sup-
pression. We considered any serum estradiol level in the
normal postmenopausal range of 20 pmol/mL to indicate
loss of aromatase inhibition. Estradiol levels were com-
pared before and after the intervention using the Wilcoxon
signed rank test [29]. An interim analysis was performed
after the 10 patients on the 300-g dose completed therapy
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to confirm estradiol suppression after therapy and to assess
for symptom improvement prior to implementing the
150-g dose of testosterone.
The secondary endpoint of clinical effect was analyzed
based on serial questionnaire results. Improvement in
symptom scores was calculated using the total scores for
each patient and for each individual symptom using the
Wilcoxon signed rank test. Power was calculated using
the two-sided hypothesis that testosterone cream affects the
symptoms of vaginal atrophy. We sought to detect differ-
ences in the symptom scores of at least 0.4 points on a 0–3
scale. For the effect of treatment, assuming a standard de-
viation of 0.5 with a two-sided   0.05 and a paired com-
parison, a sample size of 16 subjects has 89% power. To
accommodate the loss of power anticipated from using non-
parametric tests, we sought 20 patients. For comparisons
between the two dosing levels, the analysis is unpaired.
Therefore we were only powered to detect a difference of
0.6 points in the symptom score.
The secondary endpoint of pathologic improvement of
vaginal atrophy was analyzed based on a comparison of
baseline and post-treatment maturation index, pH, and clin-
ical examination. Maturation indices were compared using
the Wilcoxon signed rank test [18]. The maturation index is
a score of 0–100 based on the ratio of parabasal, interme-
diate, and superficial squamous cells, with a score 50 sig-
nifying atrophy. Studies of topical estrogen therapies
typically show an improvement in the maturation index
from in the 40s to in the 60s, with an increase in maturation
index 10. We thus considered an improvement in the mat-
uration index 10 to be significant. A drop in vaginal pH
from 5 to 5 correlates with the presence and resolution
of vaginal atrophy [30, 31]. Pretreatment and post-treat-




Twenty-one women were enrolled between June 2007 and
September 2009. One patient declined treatment after giv-
ing consent and was not included in the analysis. Twenty
patients received treatment as planned. One patient missed
the end-of-4-weeks visit and two missed the 8-week fol-
low-up visit (4 weeks post-therapy). Patients’ ages were in
the range of 45–69 years. All had early-stage breast cancer.
The AIs used were primarily nonsteroidal imidazole com-
pounds—10 women were on anastrozole, whereas eight
were on letrozole, and two were on the steroidal AI exemes-
tane. Baseline estradiol levels were low, as expected during
AI therapy (the highest value was 6.9 pg/mL and the re-
mainder were 5 pg/mL) (Table 1). All women had mod-
erate to severe symptoms of vaginal atrophy at baseline,
with the most common symptom being vaginal dryness
and the least common being vaginal itching. Patients on
the 150-g and 300-g testosterone doses had similar base-
line symptom scores, vaginal pH, and maturation indices
(Table 1).
Hormone Levels
Serum estradiol levels remained low after therapy—18
were undetectable (5 pg/mL), one was 7 pg/mL, and one
was 7.6 pg/mL. There was no significant difference in me-
dian serum estradiol level before and after treatment (p 
.91) and no difference in post-treatment estradiol levels be-
tween dosing levels (p  .99) (Table 2). Pretreatment serum
testosterone levels were 21 ng/dL in all patients. The
level rose to 113 ng/dL in one patient, and was 42 ng/dL
in the others (Table 2).
Symptom Scores
Baseline complaints of dyspareunia were rated severe by 16
of 20 women (80%). Eight women rated vaginal dryness as
severe and three complained of severe itching or irritation.
Women had the option to mark “not applicable” instead of
rating dyspareunia. All women rated this numerically at
baseline, but four women marked “not applicable” at sub-
sequent visits (Table 2).
The mean total symptom score was 2.0 at baseline,
fell to 0.7 after treatment (p  .001), and remained low 1









Mean age (range), yrs 57 (47–66) 56 (45–69) .82
Total symptom scorea
( standard deviation)




Dryness score, median 2 2 .79
Itching score, median 1 1 .94










aSymptoms: 1, mild; 2, moderate; 3, severe.
bEstradiol 5 pg/mL and testosterone 5 ng/dL
considered equal to 0.
427Witherby, Johnson, Demers et al.
www.TheOncologist.com
month post-therapy (p  .003). The severity of dyspa-
reunia and vaginal dryness improved significantly after
treatment, but itching did not (Table 2). One month after
completion of treatment, a smaller degree of improve-
ment persisted, again significant only for dyspareunia
and vaginal dryness (Table 2). There was no significant
difference in the improvement seen between the 300-g
and 150-g dose cohorts (Table 2).
Gynecologic Examinations, Cytology, and pH
Seventeen women completed pretreatment and post-treat-
ment vaginal examinations. Maturation values rose from a
median pretreatment value of 20% to a post-treatment value
of 40% (p  0.001) (Figs. 1 and 2). The mean pH level im-
proved from 5.24 to 4.93 (p  .028). Clinical examination
revealed post-treatment improvement in signs of atrophy,
including a greater degree of lubrication, color change from
white to pink, and appearance of rugae not present on the
baseline examination in some patients.
Effect of Dose
The difference in improvement of clinical symptoms be-
tween high- and low-dose testosterone was not significant
for the mean total symptom score (1.3 versus 0.8; p 
.37) or for individual symptoms of vaginal dryness (2.0
versus 1.5; p  .9), vaginal itching (0 versus 0; p  .33),
or dyspareunia (2.0 versus 1.5; p  .13) (Table 2). Both
doses demonstrated significant improvements in dyspareu-
nia and total symptoms compared with baseline.
The change in the pathologic measurement of improve-
ment did appear to differ by dose. Post-treatment matura-
tion values were significantly different by dose, with a 60%
higher maturation index with the 300-g dose and a 20%
Figure 1. Vaginal cytology from a patient before and after treat-
ment with 300 g testosterone cream for 28 days. (A): Pretreat-
ment vaginal cytology—sparse, atrophic, parabasal cells. 400
magnification, Papanicolau stain. (B): Post-treatment vaginal cy-
tology—mix of mature intermediate and superficial squamous
cells. 400 magnification, Papanicolau stain.











Sample size 20 19 18
Total symptom score
( standard deviation)
5.9 (1.9) 2.1 (1.77) .001 1 .003
Dyspareuniaa 3 1 .001 2 .003
Dryness score, median 2 0 .001 1.5 .017
Itching score, median 1 1 .049 0 .14
Vaginal pH, median 5.5 5.0 .028 –
Maturation index, % 20 40 .001 –
Median estradiol, pg/mL 0 0 .91 –
Median testosterone, ng/dL 15.5 21.5 .022 –
aSample size for dyspareunia was 14 post-treatment and 15 at 4-week follow-up.
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higher maturation index with the 150-g dose (p  .005)
(Fig. 2B). Furthermore, nine of the 10 women on the
300-g testosterone dose demonstrated an increase in mat-
uration value to 50% whereas none of the women on the
150-g dose did (Fig. 2B).
A significant decrease in pH compared with baseline
was seen in patients on the 300-g dose (5.1 to 4.6), but not
in patients on the 150-g dose (5.4 to 5.5). Comparing these
two groups suggested that improvement in pH after treat-
ment favored the 300-g dose over the 150-g dose, al-
though this was not significant (0 versus 0.5; p  .09)
(Fig. 2B).
Toxicity
Specific complaints likely related to testosterone included
mild symptoms of abnormal hair growth (n  2), acne (n  1),
vaginal rash (n  1), and pruritis (n  1) and moderate symp-
toms of vaginal discharge (n  1). One month post-therapy,
one woman noted a nonvaginal rash. Symptoms that improved
during therapy included acne (n  1), depression (n  2), and
vaginal and thigh “burning” (n  1). One woman had an ele-
vation in alanine aminotransferase to ECOG grade 1 that tran-
siently increased to grade 2 after treatment [17]. No elevations
in hematocrit or cholesterol levels were observed. No patients
stopped therapy because of side effects.
DISCUSSION
Twenty-eight days of topical testosterone was associated
with improved symptoms of vaginal atrophy in 20 women
on AIs without raising estradiol levels. Clinical improve-
ment waned but was not lost 1 month after therapy. The
treatment was well tolerated. This is an important finding
because vaginal atrophy is common among patients on AI
therapy and current treatment strategies are either ineffec-
tive or pose potential risks.
The literature on the use of topical testosterone by
women on AIs is limited. Recent reports support the use of
androgens and testosterone in women with vaginal atrophy
and research is ongoing into the effectiveness of pilo-
carpine, a nonselective muscarinic receptor agonist
[32–36]. A recently completed trial of intravaginal dehy-
droepiandrosterone (Prasterone) showed an effect on vagi-
nal atrophy without elevation of estradiol or testosterone
above usual postmenopausal levels [37]. Preliminary re-
sults from one study of vaginal testosterone in women on
AIs are available [30]. Testosterone was applied at a dose
of 500 g daily for 2 weeks then three times per week for
10 weeks, which improved vaginal atrophy and sexual
function. This supports our result on the clinical effec-
tiveness of testosterone. However, modest elevations in
estradiol were noted in some patients, even after treat-
ment ceased. This underscores the importance of finding
the lowest effective dose of testosterone in this popula-
tion.
The lowest effective dose of testosterone is also impor-
tant for its effect on serum testosterone levels. Although the
association between testosterone therapy and elevated se-
rum testosterone levels on initial and recurrent breast can-
cer risk is controversial, the elevation in testosterone levels
in several patients in this study is concerning. The most sig-
nificant increase in serum testosterone occurred in our first
patient. Modifications in the application of the cream me-
diated levels and subsequent patients had either no or small
increases in serum testosterone. Several studies suggest that
a possible greater breast cancer risk associated with testos-
terone is indirectly mediated by greater conversion to estro-
gen. This would theoretically not occur in the presence of
aromatase inhibition; however, other studies suggest that
this effect is mediated directly by testosterone, which
would not be countered by aromatase inhibition. Observa-
tional and case–control studies reviewing the association of
higher levels of serum testosterone with more frequent and
recurrent breast cancer diagnoses are conflicting [38–44].
Figure 2. Pretreatment and post-treatment pathology results
by dose level. (A): Change in maturation index (%). (B):
Change in pH.
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Testosterone prescribed for low libido is associated with a
higher risk for an initial breast cancer diagnosis in some, but
not all, studies [45, 46]. Data on testosterone levels in pa-
tients on AIs are lacking. Thus, it is prudent to closely mon-
itor the effects of this treatment on serum testosterone in
future studies of testosterone in this population.
The main limitation of this study is the lack of concur-
rent controls, which leaves our findings vulnerable to re-
gression to the mean. The recruitment of subjects was not
systematic, which may limit the generalization of this small
sample of patients to other populations. Without concurrent
controls, it is also not possible to judge how much effect
was related to the cream base as opposed to the testosterone
alone. Future studies will be randomized with a control arm
of the cream or Replens moisturizer.
One of the strengths of our study is the consistency of
findings across a variety of measurements. Although the
self-reported symptoms are subjective, they are supported
by the pathologic improvement seen in the blinded compar-
ison of vaginal cytology. The pathologic correlates of pH
and the maturation index only improved significantly in
the cohort on 300 g testosterone. Interestingly, despite
the lack of a pathologic response at the lower dose, there
was no difference in symptom outcomes at the different
doses of testosterone studied. Given the equivalent effect
on symptoms, use of the lower dose may be prudent. Al-
ternatively, the effect of the higher dose on the thinness
of the vaginal epithelium may be associated with greater
effectiveness, similar to the difference between symptom
improvement with topical estrogens, which reverse the
cytologic changes of vaginal atrophy, and with Replens,
which does not [8].
Our findings are preliminary and require confirmation
in controlled studies before clinical recommendations can
be made. The doses in this study, however, provide a rea-
sonable starting point for further testing because we were
able to demonstrate clinical efficacy and tolerance in this
small cohort of subjects.
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